SavedAdd your journal

Journals / ANKEM Dergisi / 2005 / Cilt: 19 - Sayı: 1

Discussion of the diagnosis and treatment of visceral leishmaniasis on the occasion of a case

Bir olgu nedeniyle visseral leishmaniasis tanı ve tedavisinin tartışılması

M. Bülent ERTUĞRUL
HATİCE ERTABAKLAR
Güliz UYAR
SEMA ERTUĞ
Serhan SAKARYA
Pages
48–51
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The patient was successfully treated with pentavalent antimonial (Glucantime®).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Leishmaniasis, aprotozoal infection, is still an important public health problem.
📊
Key Findings & Data:New non-invasive and accurate tests are being developed in the diagnosis of VL.
💡
Conclusion & Impact:The patient was successfully treated with pentavalent antimonial (Glucantime®).
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Şark çıbanı · visseral · Tanı teknik ve işlemleri

Abstract

Leishmaniasis, aprotozoal infection, is still an important public health problem. Visceral leishmaniasis (VL) is the fatal form of the disease in the absence of treatment. New non-invasive and accurate tests are being developed in the diagnosis of VL. On the other hand, clinical findings of VL and malaria are similar and this makes the differential diagnosis difficult. Amphotericin-B lipid formulations are being widely used in the treatment of the disease instead of pentavalent antimonials. In this case report; a patient clinically diagnosed as malaria was sent first to malaria clinic. Due to the lack of microscopic visualization of Plasmodium, the patient was referred to our clinic. Immunochromatographic test for rK39 antibodies was found positive. The serum sample contained a high titer (1:512) of anti-Leishmania antibodies in indirect fluorescent antibody test. The definitive diagnosis was based on the microscopic visualization of the amastigote stage of the parasite in bone marrow aspirate. The patient was successfully treated with pentavalent antimonial (Glucantime®).

Özet

Bir protozoon hastalığı olan leishmaniasis ciddi bir halk sağlığı problemi olmaya devam etmektedir, vlsseral leishmaniasis (VL), tedavi edilmediği durumda hastalığın ölümcül olabilen bir formudur. VL tanısında invazifolmayan ve kesin sonuçlar veren yeni testler geliştirilmektedir. Diğer taraftan VL ve sıtmanın klinik bulguları birbirine benzerdir ve bu da ayırıcı tanıda zorluklar yaratmaktadır. Hastalığın tedavisinde beş değerli antimon bileşikleri yerine lipid formülasyonlu amfoterisin-B kullanımı giderek yaygınlaşmaktadır. Olgumuz klinik bulgular nedeniyle sıtma ön tanısı ile önce sıtma savaş polikliniğine gönderilmiş, mikroskopik olarak sıtma parazitleri gösterilemediğinden kliniğimize sevk edilmiştir. Hastanın immunokromatografik dipstik testinde rK39 antikorları pozitif bulunmuştur, indirekt floresan antikor testi ile 1/512 titrede Leishmania 'ya özgül IgG antikoru saptanmıştır. Kesin tanı kemik iliği aspirasyon örneğinde parazitin amastigot formunun görülmesi ile konmuştur. Hasta beş değerli antimon bileşiği (Glucantime®) ile başarılı bir şekilde tedavi edilmiştir.

🔖

Cite This Article

ERTUĞRUL, M. B., ERTABAKLAR, H., UYAR, G., ERTUĞ, S., SAKARYA, S. (2005). Discussion of the diagnosis and treatment of visceral leishmaniasis on the occasion of a case. ANKEM Dergisi, Cilt: 19 - Sayı: 1, 48–51. https://ajindex.com/articles/207597

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Akman L, Aksu HS, Wang RQ et al: Multi-site DNA polymorphism analyses of Leishmania isolates define their genotypes predicting clinical epidemiology of leishmaniasis in a specific region, J Eukaryot Microbiol 2000;47(6):545-54
  2. Bodur H, Korkmaz M, Akıncı E, Çolpan A, Eren SS, ErbayA:Visseral layşmanyaz: İki olgu bildirisi, Klinik Derg 2003;16(2):95-7
  3. Boelaert M, Lynen L, Desjeux P, Van Der Stuyft P: Cost-effectiveness of competing diagnostic-therapeutic strategies for visceral leishmaniasis, Bull World Health Organ 1999;77(8):667-74
  4. Buyukasik Y, Ileri NS, Haznedaroglu IC, Demiroglu H, Dundar S: Fever, hepatosplenomegaly and pancytopenia in a patient living in the Mediterranean region, Postgrad Med J 1998;74:237-9
  5. Davidson RN, Di Martino L, Gradoni L et al: Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome), Clin Infect Dis 1996;22(6):938-43
  6. Desjeux P: Leishmaniasis. Public health aspects and control, ClinDermatol 1996;14:417-23
  7. Desjeux P: Leishmaniasis: Current situation and newperspectives, Comp Immunol Microbiol Infect Dis 2004;27(5):305-18
  8. Desjeux P: Worldwide increasing risk factors for leishmaniasis, Med Microbiol Immunol (Berl) 2001;190(2):77-9
  9. Ertuğ S,Aydın N, Gültekin B, Doyuran ES: 2001 yılında Aydın İl Sağlık Müdürlüğü'ne ihbar edilen iç organ ve deri leishmaniasis olguları,Adnan Menderes Üniv Tıp Fak Derg 2002;3(1):9-12
  10. Guerin PJ, Olliaro P, Sundar S et al: Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda, Lancet Infect Dis 2002;2:494-501
  11. LagunaDel Estal P,MoyaMS,MartinT,LuceroMJ, SalgadoR:Metronidazole therapy for visceral leishmaniasis, Clin Infect Dis 1994;19:1161-2
  12. Meyerhoff A:U.S. Food and Drug Administration approval of Am Bisome (liposomal amphotericin B) for treatment of visceral leishmaniasis, Clin Infect Dis 1999;28(1):42-8
  13. Minodier P, Garnier JM: Childhood visceral leishmaniasis in Provence, Arch Pediatr 2000;7(Suppl 3):572s-7s
  14. Molina R,Amela C, Nieto J et al: Infectivity of dogs naturally infected with Leishmania infantum to colonized Phlebotomus perniciosus, Trans R Soc Trop Med Hyg 1994;88(4):491-3
  15. Ok UZ, Balcioglu IC,Taylan Ozkan A, Ozensoy S, Ozbel Y: Leishmaniasis in Turkey, Acta Trop 2002;84(1):43-8
  16. Thakur CP, Sinha GP, Sharma V, Pandey AK, Sinha PK, Barat D: Efficacy of amphotericin B in multi-drug resistant kala-azar in children in first decade o